Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $11.45.

Several analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Evercore ISI boosted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Piper Sandler restated an “overweight” rating and issued a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th.

Health Catalyst Stock Down 5.8 %

Health Catalyst stock opened at $6.49 on Tuesday. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.06. The business has a fifty day moving average of $7.77 and a two-hundred day moving average of $7.55. The firm has a market cap of $394.90 million, a P/E ratio of -4.81 and a beta of 1.36. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the previous year, the company posted ($0.22) earnings per share. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, analysts forecast that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the sale, the chief financial officer now owns 86,712 shares in the company, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $160,309.76. Following the completion of the sale, the general counsel now directly owns 72,250 shares of the company’s stock, valued at approximately $601,120. This trade represents a 21.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 74,727 shares of company stock worth $601,810 in the last quarter. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. lifted its holdings in shares of Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares during the period. Harbor Capital Advisors Inc. raised its position in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after buying an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Health Catalyst by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after acquiring an additional 2,164 shares during the period. Creative Planning boosted its holdings in shares of Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after acquiring an additional 2,486 shares in the last quarter. Finally, Quarry LP increased its stake in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.